Abstract:BRCA1/2 mutations predispose to early onset breast and ovarian cancers. The phenotypic expression of mutant alleles, however, is thought to be modified by factors that are also involved in the pathogenesis of sporadic breast cancer. One such protein is IGF-I, one of the strongest mitogens to breast cancer cells in vitro. We have utilized immunohistochemistry to compare the intratumoral IGF-I and IGF-I receptor (IGF-IR) protein expression in 57 BRCA1/2 mutation carriers and 102 matched breast cancer patients wi… Show more
“…[26]in1991dem-onstrated mRNA for IGF-I in 3 of 10 human ovarian cell lines and in 7 of 7 primary and metastatic ovarian cancer surgicalspecimensbyRNaseprotectionassay.Thecelllines and surgical specimens predominantly expressed an IGF-I mRNAtranscriptwithanalternatefirstexon.Inagroupof patientswithinvasiveovariancancers,IGF-Ilevelsinfluids obtainedfromtumorsweresignificantlymoreelevatedthan influidsfrombenigncystsorborderlinetumors [7].Similar resultshavebeenfound,notonlyinovariancancer,butalso in other malignant disease [27,[29][30][31]. IGF-I gene expressionwasincreasedincolorectalcancerwhencomparedwith adjacentnormalmucosa [27],andthelocaleffectsofIGF-I are important in colorectal tumorigenesis and tumor neovascularization [28].…”
Section: Discussionmentioning
confidence: 79%
“…IGF-I gene expressionwasincreasedincolorectalcancerwhencomparedwith adjacentnormalmucosa [27],andthelocaleffectsofIGF-I are important in colorectal tumorigenesis and tumor neovascularization [28]. High levels of IGF-I expression were alsofoundinbreastcancer [29],glioma [30],andpancreatic cancer [31].…”
Background: Epidemiological evidence supports a role for the insulin-like growth factors (IGFs) and their receptor, IGF-IR, in the induction and progression of various cancers. Estrogen receptor alpha (ERΑ), which plays a role in the etiology of ovarian cancer, both regulates and is influenced by the IGF family. Patients and Methods: We present a case control study conducted in the Northeast region of China between 2007 and 2008. Fresh specimens were collected from ovarian cancer patients and matched controls who underwent surgery for benign diseases. IGF-I, IGF-IR, and ERΑexpression was analyzed using quantitative real-time polymerase chain reaction. Results: Expression of IGF-I and IGF-IR was increased in ovarian cancer compared to benign tumors. The association was dose-dependent and was more evident in premenopausal women than in postmenopausal women. Both IGF-I and IGF-IR expression were found to be higher in tumors with poor prognosis. Patients with either suboptimal debulking or with residual tumor after surgery had slightly higher IGF-IR expression. Intratumoral IGF-I expression was positively correlated with the expression of IGF-IR, but not with ERΑ. Conclusion: The increased intratumoral IGF-I and IGF-IR expression suggests an involvement of the IGF-I/IGF-IR axis in the biological behavior of ovarian cancers in this population and could define a potential therapeutic target.
“…[26]in1991dem-onstrated mRNA for IGF-I in 3 of 10 human ovarian cell lines and in 7 of 7 primary and metastatic ovarian cancer surgicalspecimensbyRNaseprotectionassay.Thecelllines and surgical specimens predominantly expressed an IGF-I mRNAtranscriptwithanalternatefirstexon.Inagroupof patientswithinvasiveovariancancers,IGF-Ilevelsinfluids obtainedfromtumorsweresignificantlymoreelevatedthan influidsfrombenigncystsorborderlinetumors [7].Similar resultshavebeenfound,notonlyinovariancancer,butalso in other malignant disease [27,[29][30][31]. IGF-I gene expressionwasincreasedincolorectalcancerwhencomparedwith adjacentnormalmucosa [27],andthelocaleffectsofIGF-I are important in colorectal tumorigenesis and tumor neovascularization [28].…”
Section: Discussionmentioning
confidence: 79%
“…IGF-I gene expressionwasincreasedincolorectalcancerwhencomparedwith adjacentnormalmucosa [27],andthelocaleffectsofIGF-I are important in colorectal tumorigenesis and tumor neovascularization [28]. High levels of IGF-I expression were alsofoundinbreastcancer [29],glioma [30],andpancreatic cancer [31].…”
Background: Epidemiological evidence supports a role for the insulin-like growth factors (IGFs) and their receptor, IGF-IR, in the induction and progression of various cancers. Estrogen receptor alpha (ERΑ), which plays a role in the etiology of ovarian cancer, both regulates and is influenced by the IGF family. Patients and Methods: We present a case control study conducted in the Northeast region of China between 2007 and 2008. Fresh specimens were collected from ovarian cancer patients and matched controls who underwent surgery for benign diseases. IGF-I, IGF-IR, and ERΑexpression was analyzed using quantitative real-time polymerase chain reaction. Results: Expression of IGF-I and IGF-IR was increased in ovarian cancer compared to benign tumors. The association was dose-dependent and was more evident in premenopausal women than in postmenopausal women. Both IGF-I and IGF-IR expression were found to be higher in tumors with poor prognosis. Patients with either suboptimal debulking or with residual tumor after surgery had slightly higher IGF-IR expression. Intratumoral IGF-I expression was positively correlated with the expression of IGF-IR, but not with ERΑ. Conclusion: The increased intratumoral IGF-I and IGF-IR expression suggests an involvement of the IGF-I/IGF-IR axis in the biological behavior of ovarian cancers in this population and could define a potential therapeutic target.
“…In addition, intact BRCA1 protein can lower IGF-1 receptor levels in breast cancer cells (Hudelist et al, 2007;Maor et al, 2007). Klotho-V allele shows reduced excretion and enzymatic activity (Figure 2b; Arking et al, 2002).…”
Klotho is a transmembrane protein that can be shed and act as a circulating hormone and is a putative tumor suppressor in breast cancer. A functional variant of KLOTHO (KL-VS) contains two amino acid substitutions F352V and C370S and shows reduced activity. Germ-line mutations in BRCA1 and BRCA2 substantially increase lifetime risk of breast and ovarian cancers. Yet, penetrance of deleterious BRCA1 and BRCA2 mutations is incomplete even among carriers of identical mutations. We examined the association between KL-VS and cancer risk among 1115 Ashkenazi Jewish women: 236 noncarriers, 631 BRCA1 (185delAG, 5382insC) carriers and 248 BRCA2 (6174delT) carriers. Among BRCA1 carriers, heterozygosity for the KL-VS allele was associated with increased breast and ovarian cancer risk (hazard ratio 1.40, 95% confidence intervals 1.08-1.83, P ¼ 0.01) and younger age at breast cancer diagnosis (median age 48 vs 43 P ¼ 0.04). KLOTHO and BRCA2 are located on 13q12, and we identified linkage disequilibrium between KL-VS and BRCA2 6174delT mutation. Studies in breast cancer cells showed reduced growth inhibitory activity and reduced secretion of klotho F352V compared with wildtype klotho. These data suggest KL-VS as a breast and ovarian cancer risk modifier among BRCA1 mutation carriers. If validated in additional cohorts, the presence of KL-VS may serve as a predictor of cancer risk among BRCA1 mutation carriers.
“…IGF1R and DNA-damaging agents BRCA-mutated breast cancers are susceptible to the impairment of DNA damage repair by homologous recombination and interestingly are known to have high IGF-1 protein expression (Hudelist et al 2007). Specific therapies aimed at targeting DNA repair factors include poly ADPribose polymerase (PARP) inhibitors (e.g.…”
Insulin-like growth factor receptor (IGF1R) signaling as a therapeutic target has been widely studied and clinically tested. Despite the vast amount of literature supporting the biological role of IGF1R in breast cancer, effective clinical translation in targeting its activity as a cancer therapy has not been successful. The intrinsic complexity of cancer cell signaling mediated by many tyrosine kinase growth factor receptors that work together to modulate each other and intracellular downstream mediators in the cell highlights that studying IGF1R expression and activity as a prognostic factor and therapeutic target in isolation is certainly associated with problems. This review discusses the current literature and clinical trials associated with IGF-1 signaling and attempts to look at new ways of designing novel IGF1R-directed breast cancer therapy approaches to target its activity and/or intracellular downstream signaling pathways in IGF1R-expressing breast cancers.
23:11
Review
A M Ochnik and R C BaxterDual IGF-directed breast cancer therapies
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.